Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug;53(8):e2249919.
doi: 10.1002/eji.202249919. Epub 2023 Apr 3.

Immunoregulation of asthma by type 2 cytokine therapies: Treatments for all ages?

Sejal Saglani  1   2 , Laura Yates  1 , Clare M Lloyd  1
Affiliations
Free article
Review

Immunoregulation of asthma by type 2 cytokine therapies: Treatments for all ages?

Sejal Saglani et al. Eur J Immunol. 2023 Aug.
Free article

Abstract

Asthma is classically considered to be a disease of type 2 immune dysfunction, since many patients exhibit the consequences of excess secretion of cytokines such as IL-4, IL-5, and IL-13 concomitant with inflammation typified by eosinophils. Mouse and human disease models have determined that many of the canonical pathophysiologic features of asthma may be caused by these disordered type 2 immune pathways. As such considerable efforts have been made to develop specific drugs targeting key cytokines. There are currently available multiple biologic agents that successfully reduce the functions of IL-4, IL-5, and IL-13 in patients, and many improve the course of severe asthma. However, none are curative and do not always minimize the key features of disease, such as airway hyperresponsiveness. Here, we review the current therapeutic landscape targeting type 2 immune cytokines and discuss evidence of efficacy and limitations of their use in adults and children with asthma.

Keywords: Asthma; Asthma biologics; Immunoregulation; type 2.

PubMed Disclaimer

References

    1. Tu, L., Chen, J., Zhang, H. and Duan, L., Interleukin-4 inhibits regulatory T cell differentiation through regulating CD103+ dendritic cells. Front. Immunol. 2017. 8: 214.
    1. Palomares, O., Akdis, M., Martin-Fontecha, M. and Akdis, C. A., Mechanisms of immune regulation in allergic diseases: the role of regulatory T and B cells. Immunol. Rev. 2017. 278: 219-236.
    1. Coyle, A. J., Le Gros, G., Bertrand, C., Tsuyuki, S., Heusser, C. H., Kopf, M., Anderson, G. P. et al., Interleukin-4 is required for the induction of lung Th2 mucosal immunity. Am. J. Respir. Cell Mol. Biol. 1995. 13: 54-59.
    1. Tepper, R. I., Levinson, D. A., Stanger, B. Z., Campos-Torres, J., Abbas, A. K. and Leder, P., IL-4 induces allergic-like inflammatory disease and alters T cell development in transgenic mice. Cell 1990. 62: 457-467.
    1. Fukuda, T., Fukushima, Y., Numao, T., Ando, N., Arima, M., Nakajima, H., Sagara, H. et al., Role of interleukin-4 and vascular cell adhesion molecule-1 in selective eosinophil migration into the airways in allergic asthma. Am. J. Respir. Cell Mol. Biol. 1996. 14: 84-94.